Patents by Inventor Mircea A. Mateescu

Mircea A. Mateescu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cross-linked amylose as a binder/disintegrant in tablets
    Patent number: 5616343
    Abstract: The present invention is concerned with the manufacture of solid dosage units (pharmaceutical and others). More specifically, the invention is related to powders of cross-linked amylose, having a specific cross-linking degree for use as tablet binders and disintegrants.
    Type: Grant
    Filed: March 25, 1993
    Date of Patent: April 1, 1997
    Assignee: Labopharm, Inc.
    Inventors: Louis Cartilier, Mircea A. Mateescu, Yves Dumoulin, Vincent Lenaerts
  • Cross-linked enzymatically controlled drug release
    Patent number: 5603956
    Abstract: The present application is concerned with a solid slow release pharmaceutical dosage unit. More specifically, the invention is directed to a tablet form prepared by direct compression of cross-linked amylose (CLA) having a definite cross-linking degree, .alpha.-amylase and a pharmaceutical agent. The presence of the cross-linked amylose allows a sustained release of the drug, while the .alpha.-amylase permits the modulation of the release time. In other words, the release time of the drug is function of the amount of .alpha.-amylase in the tablet. The amount of .alpha.-amylase is defined in terms of Enzyme Units.
    Type: Grant
    Filed: June 16, 1994
    Date of Patent: February 18, 1997
    Assignee: Labopharm Inc.
    Inventors: Mircea A. Mateescu, Yves Dumoulin, Louis Cartilier, Vincent Lenaerts
  • Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
    Patent number: 5456921
    Abstract: The present invention is concerned with a solid slow release oral pharmaceutical dosage unit which comprises a solid dosage unit made up of an admixture of a therapeutic dosage of an orally effective pharmaceutical product and a cross-linked polymer of amylose with a cross-linking agent selected from 2,3 dibromopropanol and epichlorohydrin, wherein the cross-linking of the polymer has been carried out with from about 0.1 to about 10 g of cross-linking agent per 100 g of amylose.
    Type: Grant
    Filed: February 9, 1994
    Date of Patent: October 10, 1995
    Assignee: Labopharm, Inc.
    Inventors: Mircea A. Mateescu, Vincent Lenaerts, Yves Dumoulin